A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : p-tau / phospho-tau

[Related PubMed/MEDLINE]
Total Number of Papers: 42
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   p-tau  (>> Co-occurring Abbreviation)
Long Form:   phospho-tau
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging. AD, CSF, TEMT
2019 Associations of regional amyloid-beta plaque and phospho-tau pathology with biological factors and neuropsychological functioning among HIV-infected adults. APOE, OR
2019 High Levels of beta-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. AD, alpha-syn, IL-1beta, ND, RBCs
2019 Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. AD, CSF
2019 Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach. aSyn, CSF, DL, sCJD, t-tau
2019 TREML2 Mutation Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. AD, ADAS-cog 11, ADNI, CDRSB, CSF, MCI, MMSE, RAVLT, t-tau, TREML2
2018 Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. HD, NFL, t-tau
2018 Ethyl acetate fraction from Hibiscus sabdariffa L. attenuates diabetes-associated cognitive impairment in mice. CQA, DM, MWM, p-JNK, STZ
2017 Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. AD, CSF, t-tau
10  2016 3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish". AD, FAD, HTS, iPSCs, NFTs
11  2016 Clinical Consensus Guidelines on the Application of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: Recommendations of the Irish Network for Biomarkers in Neurodegeneration. Abeta42, AD, CSF, LP, t-tau
12  2016 Ginsenosides attenuate d-galactose- and AlCl3-inducedspatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer's disease. AD, d-gal, MWM
13  2016 Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway. AD, t-tau
14  2015 Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. AD, SNAP
15  2015 Anti-tau antibody reduces insoluble tau and decreases brain atrophy. i.p
16  2015 Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments. AD, CSF, t-tau
17  2015 Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment. MEG
18  2015 Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. AD, PFFs
19  2015 Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. AD, CSF, MC, MRI, NC, t-tau
20  2015 Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. PHF, pS404
21  2014 Alteration of thioredoxin and glutaredoxin in the progression of Alzheimer's disease. AD, Grx, MCI, Trx
22  2014 Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Abeta42, AD, APP, NPH, t-tau
23  2014 Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. AD, AMPARs, Drp1, eNMDAR, LTP, NMDARs
24  2014 The role of tau protein in HIV-associated neurocognitive disorders. cART, CSF, HIV, t-tau
25  2013 [Effect of aluminum trichloride on abnormal phosphorylation of tau protein in SH-SY5Y cells]. ---
26  2011 Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. AD, CSF, NFT
27  2011 Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. CSF
28  2011 Chemokines in CSF of Alzheimer's disease patients. AD, BA, CSF
29  2009 CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. AD, CSF, MCI, MFV, PI, t-tau, TCD, WMC
30  2009 Inflammatory markers in AD and MCI patients with different biomarker profiles. MCI
31  2008 Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. CSF, MIM, SIM, T-tau
32  2008 Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, MRI and negative 14-3-3 immunoblot. CSF, EEG, MRI, MRS, sCJD, t-tau
33  2008 p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease. AD
34  2006 Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. AD, CSF, MCI
35  2005 Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. AD, CSF, ELISA, t-tau, VD
36  2005 Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. CJD, CSF, t-tau
37  2005 [New investigations in suspected Creutzfeldt-Jakob disease. Analysis of 14-3-3 protein and T-tau in cerebrospinal fluid for safer diagnosis]. CJD, CSF, t-tau
38  2004 CSF biomarkers for mild cognitive impairment. AD, CSF, MCI, MRT, t-tau
39  2003 Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. CSF, MRI, t-tau
40  2003 Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. AD, CSF, MCI, t-tau
41  2003 CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. AD, CSF, t-tau
42  2003 Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. AD, CJD, CSF, FTD